Brain Function and EEG

NCT ID: NCT05003076

Last Updated: 2024-01-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-07-01
• Study Completion Date: 2023-04-01

Brief Summary

In this project, we will examine effects of MA on reward function using electroencephalograms (EEG), which will complement our ongoing study with MA and fMRI. We will determine how MA alters reward-related neural activity and how this is related to its subjective rewarding effects. The effects of MA on reward function will be examined using both reward-task-related activation and resting state activity. We will examine the effects of MA on ratings of drug liking and euphoria, as well as on EEG measures sensitivity to reward. Healthy young adults will undergo three EEG sessions with placebo and MA (10 and 20 mg), while performing the Monetary Incentive Delay task and the Stop Task, as a measure of inhibition. We will examine correlations between the neural responses and subjective responses to MA.

Our central hypotheses are 1) that MA will increase feelings of alertness and well-being, and 2) that MA will increase neural responses to anticipation and receipt of reward, and 3) that the effects of MA on mood will be correlated with its effects on neural responses to reward.

Conditions

Healthy; Mood

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: QUADRUPLE

Study Groups

Placebo Then Methamphetamine

Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive 20 mg methamphetamine.

Group Type: EXPERIMENTAL

Methamphetamine

Intervention Type: DRUG

Participants will be given 20 mg of Methamphetamine.

Placebo

Intervention Type: DRUG

Participants will be given a placebo capsule that will only contain lactose.

Methamphetamine Then Placebo

Participants first receive 20 mg methamphetamine at their first session in the laboratory Then will return to the laboratory 72 hours later and will receive placebo.

Group Type: EXPERIMENTAL

Methamphetamine

Intervention Type: DRUG

Participants will be given 20 mg of Methamphetamine.

Placebo

Intervention Type: DRUG

Participants will be given a placebo capsule that will only contain lactose.

Interventions

Methamphetamine

Participants will be given 20 mg of Methamphetamine.

Intervention Type: DRUG

Placebo

Participants will be given a placebo capsule that will only contain lactose.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

BMI between 19 and 26 Less than 4 alcohol or caffeinated beverages a day.

Exclusion Criteria

High blood pressure

Any medical condition requiring regular medication Individuals with a current (within the last year) DSM-IV Axis 1 diagnosis Individuals with a history of dependence on stimulant drugs Women who are pregnant or trying to become pregnant.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 35 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Chicago

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Harriet de Wit

Role: PRINCIPAL_INVESTIGATOR

University of Chicago

Locations

University of Chicago

Chicago, Illinois, United States

Countries

United States

Other Identifiers

IRB21-0769

Identifier Type: -

Identifier Source: org_study_id